Drugs / coltuximab ravtansine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT00796731 | Oct 2008 → Jun 2012 | non-Hodgkin lymphoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00549185 | Oct 2007 → Jan 2012 | non-Hodgkin lymphoma | Sanofi | Completed | Met primary |
| Phase 23 trials | ||||||
| Phase 2 | NCT01472887 | Jan 2012 → Sep 2016 | diffuse large B-cell lymphoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01470456 | Nov 2011 → Jul 2013 | diffuse large B-cell lymphoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01440179 | Oct 2011 → May 2014 | acute lymphoblastic leukemia | Sanofi | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2014-06-01 | AbbVie | Results ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data with Sanofi's SAR3419 in Diffuse Large B-Cell Lymphoma abbvie.com ↗
In the data presented today, study investigators reported achievement of proof of concept, with 43.9% objective response rate (ORR) for the per protocol population (patients with relapsed or relapsed/refractory disease). |
| 2014-05-14 | AbbVie | Results ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 50th Annual Meeting of ASCO abbvie.com ↗
Abstracts also add to growing body of data on the significance of partner compounds, including the findings reported on the activity and tolerability of SAR3419 in the Phase II STARLYTE trial. |
| 2013-12-09 | AbbVie | Results ImmunoGen, Inc. Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population abbvie.com ↗
The combination of SAR3419 and Rituxan was found to be generally well tolerated, with no patients discontinuing therapy due to treatment emergent adverse events (TEAEs). |
| 2012-06-04 | AbbVie | Results ImmunoGen, Inc. Announces Presentation of New Clinical Data for SAR3419 abbvie.com ↗ |
| 2011-06-04 | AbbVie | Results ImmunoGen, Inc. Announces Presentation of Favorable SAR3419 Interim Clinical Data at ASCO abbvie.com ↗
33% (7/21) of patients treated with SAR3419 at its MTD (55 mg/m 2 /week) had an objective response (CR/PR). |
| 2009-12-07 | AbbVie | Results SAR3419 Phase I Study Results in non-Hodgkin's Lymphoma at ASH abbvie.com ↗
The study found that 17 of 27 (63%) patients who were response-evaluable at the time of data cut-off for presentation experienced a reduction in tumor size (7% to 86% reduction). |
| 2006-04-01 | AbbVie | Results ImmunoGen, Inc. Announces Eight Posters to be Presented at AACR on its TAP Technology and on Compounds in Development abbvie.com ↗
Results from preclinical studies evaluating the CD19-targeting TAP compound SAR3419, which is in development by the sanofi-aventis Group (abstract #3731). |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | coltuximab ravtansine | “A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma...” PMID 29748443 ↗ May 2018 |
| Known as | Coltuximab ravtansina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109286 ↗ |
| Known as | SAR3419 | “A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma...” PMID 29748443 ↗ May 2018 |
| Route | Intravenous | “Intravenous infusion” NCT00549185 ↗ |
| Target | CD19 | “a humanized anti-CD19 antibody” PMID 23426279 ↗ Feb 2013 |